2023 ASH Highlights

 

Review presentations and information shared by Dana-Farber physician-scientists at the 66th American Society of Hematology Annual Meeting & Exposition in San Diego.

Andrew Hantel, MD, Discusses Artificial Intelligence Video

Andrew Hantel, MD, Discusses Artificial Intelligence

Artificial Intelligence in patient care - research presented at ASH23 by Dana-Farber's Andrew Hantel, MD, surveys oncologists about their feelings on incorporating AI into patient care.
Andrew Hantel, MD

Andrew Hantel, MD

Medical Oncology
Jennifer Brown, MD, PhD, Discusses ALPINE Trial Video

Jennifer Brown, MD, PhD, Discusses ALPINE Trial

Jennifer Brown, MD, PhD, Dana-Farber, presented updated results of the Phase 3 randomized ALPINE trial at ASH23. The updated analysis shows in CLL/SLL treatment, zanubrutinib maintains superior progression-free survival over ibrutinib.
Jennifer R. Brown, MD, PhD

Jennifer R. Brown, MD, PhD

Medical Oncology
Omar Nadeem, MD, Discusses Immuno-PRISM Trial Video

Omar Nadeem, MD, Discusses Immuno-PRISM Trial

At #ASH23, Omar Nadeem, MD, Dana-Farber, presented findings from the phase 2 clinical trial, Immuno-PRISM. Results suggest early use of #immunotherapy may have even greater benefit for people with high-risk smoldering myeloma.
Omar Nadeem, MD

Omar Nadeem, MD

Clinical Director, Myeloma Cellular Therapies Program
Physician
Instructor in Medicine, Harvard Medical School
Reid Merryman, MD, on ct-DNA & Diffuse Large B-cell Lymphoma Video

Reid Merryman, MD, on ct-DNA & Diffuse Large B-cell Lymphoma

At #ASH23, Reid Merryman, MD, Dana-Farber, discussed results from a pilot study that uses circulating tumor DNA to reliably predict relapse in patients with diffuse large B-cell lymphoma.
Reid Merryman, MD

Reid Merryman, MD

Medical Oncology
Corey Cutler, MD, MPH, on GVHD and Stem Cell Transplant Video

Corey Cutler, MD, MPH, on GVHD and Stem Cell Transplant

A Dana-Farber trial shows an antibody drug greatly reduces the risk of severe chronic #GVHD in patients undergoing allogenic stem cell transplant. Corey Cutler, MD, MPH, at #ASH23.
Corey Cutler, MD, MPH

Corey Cutler, MD, MPH

Medical Oncology
Paul Richardson, MD, Discusses MEZI Trial Video

Paul Richardson, MD, Discusses MEZI Trial

Multiple Myeloma Research at ASH23: Dana-Farber's Paul Richardson, MD, discusses the results of the MEZI trial, which show promising efficacy results in treating relapsed/refractory multiple myeloma.
Paul Richardson, MD

Paul Richardson, MD

Medical Oncology
Shai Shimony, MD, Molecular Ontogeny in AML Video

Shai Shimony, MD, Molecular Ontogeny in AML

A study led by Shai Shimony, MD, Dana-Farber, revealed the significant impact of molecular ontogeny classification on outcomes among newly diagnosed acute myeloid leukemia patients treated with hypomethylating agents (HMA) +/- venetoclax (VEN).
Shai Shimony, MD

Shai Shimony, MD

Katie Maurer, MD, PhD, on Immune System Features and CAR-T Video

Katie Maurer, MD, PhD, on Immune System Features and CAR-T

During #ASH23, Katie Maurer, MD, PhD presented Dana-Farber research that focused on #CART therapy, which found that there are features of a patient’s immune system prior to therapy that can influence the likelihood of response.
Katie Maurer, MD

Katie Maurer, MD

Andrew Hantel, MD, Discusses Clinical Trial Disparities Video

Andrew Hantel, MD, Discusses Clinical Trial Disparities

At ASH23, Andrew Hantel, MD, Dana-Farber, presented his real-time interactive dashboard, which will help identify racial disparities in clinical trial enrollment for acute leukemia patients.
Andrew Hantel, MD

Andrew Hantel, MD

Medical Oncology
Elizabeth Lightbody, PhD, Potential Markers Multiple Myeloma Video

Elizabeth Lightbody, PhD, Potential Markers Multiple Myeloma

Elizabeth Lightbody, PhD, at #ASH23 presented results from a study identifying proteins that could serve as potential markers for disease progression & high-risk #multiplemyeloma, furthering @danafarber research in early detection.
Elizabeth Lightbody, PhD

Elizabeth Lightbody, PhD

Shayna Sarosiek, MD, Neuropathy in MGUS or Waldenstrom Macroglobulinemia Video

Shayna Sarosiek, MD, Neuropathy in MGUS or Waldenstrom Macroglobulinemia

Shayna Sarosiek, MD, at #ASH23 discusses an ongoing clinical trial at Dana-Farber that uses rituximab and acalabrutinib to treat anti-MAG neuropathy, which occurs in some patients with IgM #MGUS or #Waldenstrom macroglobulinemia.
Shayna Sarosiek, MD

Shayna Sarosiek, MD

Press Releases

Dana-Farber Showcases Research at 65th American Society of Hematology Annual Meeting and Exposition

Bispecific antibody drives myeloma precursor condition to undetectable levels in phase II trial (Abstract 206, Omar Nadeem, MD)

Antibody drug sharply reduces risk of severe chronic graft-versus-host disease in patients undergoing allogeneic stem cell transplant, trial shows (Abstract 649, Corey Cutler, MD, MPH)

Pilot study uses circulating tumor DNA to reliably predict relapse in patients with diffuse large B-cell lymphoma (DLBCL) (Abstract 527, Reid Merryman, MD)

DETERMINATION trial subgroup analysis suggests potential strategies for individualization of myeloma treatment (Abstract 4762, Paul Richardson, MD)

 

Resources

Adult Stem Cell Transplantation Program

Cellular Therapies Program

Highlights from Previous ASH Meetings

 

Subscribe

Subscribe to “Advances in Hematologic Malignancies” to receive our bi-annual enewsletter with research and clinical updates, providing comprehensive information about our Division of Hematologic Malignancies.

 

Follow us on X (formerly Twitter)